Blueprint Medicines (NASDAQ:BPMC) Full Year 2024 Results

Key Financial Results

• Revenue: US$508.8m (up 104% from FY 2023).
• Net loss: US$67.1m (loss narrowed by 87% from FY 2023).
• US$1.07 loss per share (improved from US$8.37 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Blueprint Medicines EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 7.9%.

The primary driver behind last 12 months revenue was the United States segment contributing a total revenue of US$421.8m (83% of total revenue). The largest operating expense was Research & Development (R&D) costs, amounting to US$341.4m (49% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$145.0m. Explore how BPMC's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 11% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. See our latest analysis on Blueprint Medicines' balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.